San Diego, California ( Tuesday, May 17, 2016, PDT ) – At the Paris Course on Revascularization (“EuroPCR”) being held this week in Paris, France, REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) announced positive six - month results from the first cohort of patients in the Company’s FANTOM II clinical t rial. The Company had previously announced very good acute results from the trial. The FANTOM II trial is evaluating the safety and performance of the Fantom ® sirolimus - eluting bioresorbable coronary scaffold , which was implanted in 240 patients in two cohorts between March 2015 and March 2016.
Clinical follow - up of the 117 patients in Cohort A showed a very low rate of Major Adverse Cardiac Events ( “ MACE ” ) through six months. MACE is a composite of cardiac death, myocardial infarction (“ heart attack ”) , and clinic ally - driven revascularization. The reported preliminary six - month MACE rate of 1.71 % demonstrates Fantom’s ability to effectively treat patients with coronary artery disease over this time frame.
An analysis of angiographic imaging of the first 100 patients at six month s showed that the treated coronary arteries had a mean in - segment late lumen loss (“late loss”) of 0. 21 mm . This low late loss is a desirable result that historically correspond s to positive long - term outcomes, and compares to p ermanent drug - eluting stents and competitive bioresorbable scaffolds that generally have late loss values in the range of 0.20 mm to 0.40 mm.
"The current results from the FANTOM II clinical trial are very encouraging,” stated Dr. Alexandre Abizaid, co - p rincipal investigator for the trial and Director of Invasive Cardiology at Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil . “We look forward to continuing to follow our p atients that have been treated with Fantom and provid ing longer - term data ."
The presentation materi als delivered at the conference are available in the Investor Relations section of REVA’s website at www.revamedical.com.
REVA is a clinical stage medical device company located in San Diego, California, USA, that is working to commercializ e its proprietary bioresorbable stents, which are called “scaffolds .” The Company’s scaffolds have been developed as an alternative to metal stents, which are small tube - like devices permanently implanted into an artery to treat coro nary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the ar tery, a result not attainable with permanent metal stents. The Company’s initial product, the Fantom ® scaffold, has been designed to offer an ideal balance of thinness and strength and distinct ease - of - use features including complete scaffold visibility un der x - ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other product.
Forward - Looking Statements
This a nnouncement contains or may contain forward - looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including t hose statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward - looking statements, such as those statements regarding our ability to obtain regulatory approvals, timel y and successfully complete our clinical trials, protect our intellectual property position, commercialize our products if and when approved, develop and commercialize new products, recruit and retain our key personnel, and estimates regarding our capital requirements and financial performance. You should not place undue reliance on forward - looking statements. Although management believes forward - looking statements are reasonable as and when made, forward - looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in forward - looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10 - K filed with t he US Securities and Exchange Commission (the “SEC”) on March 10, 2016 , and as may be updated in our periodic reports thereafter. Any forward - looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation t o publicly update or revise any forward - looking statements, whether as a result of new information, future events, or otherwise.
Investor & Media Enquiries:
REVA Medical, Inc.
+61 438 217 279
+61 408 333 452
+61 3 9866 4722